J P Reckless

Summary

Affiliation: University of Bath
Country: UK

Publications

  1. ncbi Cost-effectiveness of statins
    J P Reckless
    Department of Endocrinology, Diabetes and Metabolism, Royal United Hospital, Bath, UK
    Curr Opin Lipidol 11:351-6. 2000
  2. ncbi Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study
    J P D Reckless
    Royal United Hospital, Bath, UK
    Int J Clin Pract 62:539-54. 2008
  3. ncbi Fluvastatin
    J M Lawrence
    Clinical Research Fellow, Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital, Bath, UK
    Expert Opin Pharmacother 3:1631-41. 2002
  4. ncbi The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes
    J M Lawrence
    Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital, Wolfson Centre Combre Park, Bath, UK
    Atherosclerosis 174:141-9. 2004
  5. ncbi Pitavastatin
    R Y A Mukhtar
    Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital, Coombe Park, Bath BA1 3NG, UK
    Int J Clin Pract 59:239-52. 2005
  6. ncbi Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone
    R Mukhtar
    Department of Endocrinology, Diabetes and Metabolism, Royal United Hospital, Bath, UK
    Diabet Med 22:6-10. 2005
  7. ncbi Empowering primary care to tackle the obesity epidemic: the Counterweight Programme
    M McQuigg
    Diabetes Centre, Royal United Hospital, Bath, UK
    Eur J Clin Nutr 59:S93-100; discussion S101. 2005

Collaborators

Detail Information

Publications7

  1. ncbi Cost-effectiveness of statins
    J P Reckless
    Department of Endocrinology, Diabetes and Metabolism, Royal United Hospital, Bath, UK
    Curr Opin Lipidol 11:351-6. 2000
    ..However, it is clear that what would normally be very cost-effective interventions will put substantial strain on health care resources because of the common nature of coronary disease and risk factors...
  2. ncbi Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study
    J P D Reckless
    Royal United Hospital, Bath, UK
    Int J Clin Pract 62:539-54. 2008
    ....
  3. ncbi Fluvastatin
    J M Lawrence
    Clinical Research Fellow, Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital, Bath, UK
    Expert Opin Pharmacother 3:1631-41. 2002
    ..Fluvastatin provides a useful option in treating hypercholesterolaemia in patients at high risk of coronary heart disease...
  4. ncbi The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes
    J M Lawrence
    Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital, Wolfson Centre Combre Park, Bath, UK
    Atherosclerosis 174:141-9. 2004
    ..Effects on HDL subfractions were largely neutral. High dose atorvastatin produces favourable effects on lipoprotein subfractions in type 2 diabetes which may enhance antiatherogenic potential...
  5. ncbi Pitavastatin
    R Y A Mukhtar
    Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital, Coombe Park, Bath BA1 3NG, UK
    Int J Clin Pract 59:239-52. 2005
    ..To date, human and animal studies have shown pitavastatin to be potentially as effective in lowering LDL-cholesterol levels as rosuvastatin; although, head-to-head studies are yet to be conducted...
  6. ncbi Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone
    R Mukhtar
    Department of Endocrinology, Diabetes and Metabolism, Royal United Hospital, Bath, UK
    Diabet Med 22:6-10. 2005
  7. ncbi Empowering primary care to tackle the obesity epidemic: the Counterweight Programme
    M McQuigg
    Diabetes Centre, Royal United Hospital, Bath, UK
    Eur J Clin Nutr 59:S93-100; discussion S101. 2005
    ..Completers' achieved more successful weight loss with 40% achieving a weight loss of 5% or more at 12 months. CONCLUSION: The Counterweight programme provides a promising model to improve the management of obesity in primary care...